Recent Updates
Recently added Catalysts

CVL-751

Phase 1

Parkinson Disease | Small molecule | Neurology |AbbVie Inc.|Last Updated: Aug 30, 2021

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment24
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT04295642A 2-Part Trial of CVL-751 in Subjects With Parkinson's DiseasePHASE1 COMPLETED 24Jan 1, 2020Jul 1, 2021Aug 30, 2021 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
CVL-751DRUGOral tablet
Unlock Study Design Details